Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial
Nadine Rouphael, Lilin Lai, Sonia Tandon, Michele Paine McCullough, Yunchuan Kong, Sarah Kabbani, Muktha S. Natrajan, Yongxian Xu, Yerun Zhu, Dongli Wang, Jesse O’Shea, Amy C Sherman, Tianwei Yu, Sébastien Henry, Devin V. McAllister, Daniel Stadlbauer, Surender Khurana, Hana Golding, Florian Krammer, Mark J. Mulligan, Mark R. Prausnitz
Abstract
In a phase 1 randomized, single-center clinical trial, inactivated influenza virus vaccine delivered through dissolvable microneedle patches (MNPs) was found to be safe and immunogenic. Here, we compare the humoral and cellular immunologic responses in a subset of participants receiving influenza vaccination by MNP to the intramuscular (IM) route of administration. We collected serum, plasma, and peripheral blood mononuclear cells in 22 participants up to 180 days post-vaccination. Hemagglutination inhibition (HAI) titers and antibody avidity were similar after MNP and IM vaccination, even though MNP vaccination used a lower antigen dose. MNPs generated higher neuraminidase inhibition (NAI) titers for all three influenza virus vaccine strains tested and triggered a larger percentage of circulating T follicular helper cells (CD4 + CXCR5 + CXCR3 + ICOS + PD-1+) compared to the IM route. Our study indicates that inactivated influenza virus vaccination by MNP produces humoral and cellular immune response that are similar or greater than IM vaccination.